TherapeuticsMD — Third Quarter 2026 Earnings Summary

Financial Performance:

• Net income from continuing operations totaled $501 thousand ($0.04 per basic and diluted share) for the quarter ended September 30, 2026, compared to $50 thousand ($0.00 per share) in the same period of 2025.
• License revenues from continuing operations reached $1.3 million for the quarter, representing a $475 thousand (60.6%) increase from $784 thousand in the third quarter of 2025.
• Total operating expenses from continuing operations were $1.7 million for the quarter, an increase of $92 thousand (5.6%) compared to $1.6 million in the third quarter of 2025, primarily driven by higher legal and professional fees.
• Cash and cash equivalents totaled $10.4 million as of September 30, 2026.

Guidance and Future Outlook:

• The Company expects to recognize revenue from a net sales milestone related to IMVEXXY sales for the year ending December 31, 2026, during the three months ending December 31, 2026, following notification from licensee Knight subsequent to September 30, 2026.

Business Segments and Product Lines:

• The Company operates as a pharmaceutical royalty company, collecting royalties from licensees, and has ceased research and development or commercial operations.
• A $365 thousand milestone payment related to IMVEXXY sales for the year ended December 31, 2025, was recognized and confirmed by Knight in the third quarter of 2026.

Market and Competitive Landscape:

• The Company faces risks regarding the commercial success of products licensed by third parties, competition from branded and generic products, and dependence on third parties for manufacturing and supply.

Risks and Challenges:

• Key risks include the outcome of ongoing disputes with Mayne Pharma, the ability to maintain Nasdaq listing status, the impact of government regulation and drug pricing initiatives, and the Company's ability to continue as a going concern.
• There is no assurance regarding the successful outcome, form, or timing of any strategic alternatives being explored.

Management Commentary and Tone:

• Management continues to evaluate strategic alternatives, including potential acquisitions, mergers, business combinations, or asset sales, though no timetable has been established for this process.

Other Key Points:

• TherapeuticsMD transitioned from a women's healthcare company to a pharmaceutical royalty company in December 2022.
• The Company has not established a timetable for the completion of its strategic alternatives exploration and will not disclose further developments unless deemed appropriate or necessary.